Video

Amber Salter, PhD, MPH

Publish date: May 7, 2015

Dr. Amber Salter discusses data from the NARCOMS patient registry that profile characteristics of switchers from older MS therapies to newer oral MS drugs.

 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Conference News Update—Federation of American Societies for Experimental Biology
MDedge Neurology
Can FLAIR MRI Show Treatment Efficacy?
MDedge Neurology
Using the GAD-7 Scale in Multiple Sclerosis Patients
MDedge Neurology
Concurrent Autoimmune Diseases in MS
MDedge Neurology
Does Pharmacy-Directed Treatment Management Improve Care?
MDedge Neurology
MSC Consensus Paper on DMTs in MS
MDedge Neurology
Robert Fox, MD
MDedge Neurology
Peginterferon beta-1a MS data show positive early and long-term results
MDedge Neurology
AAN: Study supports safety of fingolimod for MS
MDedge Neurology
Stacey Cofield, PhD
MDedge Neurology